If you follow the peptide news and the Ozempic news, you keep hearing the same word: compounding. It sounds like one debate. It is really two, and they sit under two different sections of federal law. Getting them straight is the fastest way to understand what just happened in a hearing room in July, and what did not.
The two sections, in plain English
Federal law carves out two kinds of legal compounding. A Section 503A pharmacy makes a medicine for a specific patient against a specific prescription. Think of the local or mail-order compounding pharmacy filling one order at a time. A Section 503B outsourcing facility is a different animal: it can make large batches, with or without patient-specific prescriptions, and sell them to clinics and hospitals. Because 503B facilities operate at manufacturing scale, they answer to a heavier rulebook, including the FDA's current good manufacturing practice standards. A 503A pharmacy is licensed and overseen primarily by its state board.
The short version: 503A is one prescription at a time; 503B is batches under federal manufacturing rules.
Which fight is which
The peptide review that an FDA advisory committee just finished is a 503A fight. The question in front of the panel was narrow: should substances like BPC-157 be added to the 503A bulk drug substances list, so a licensed pharmacy could compound them for a patient with a prescription. That is not a vote about mass production, and it is not an approval that any peptide is safe or effective.
The GLP-1 story is a different corner. When Ozempic and its cousins were in official shortage, compounders were temporarily allowed to make copies to fill the gap, and much of that volume ran through 503B-scale operations. When the shortage ended, that window narrowed. Same word, "compounding," completely different legal machinery.
Why the distinction is a supply point
Here is why we keep pulling these apart. Whichever section a medicine is compounded under, the argument Peppies makes is the same one we always make: the present danger is not the molecule, it is the unverified vial from the anonymous grey market, sold "for research use only" with no pharmacist, no prescription, and no one accountable for what is inside. A legal pharmacy pathway, 503A or 503B, at least puts a licensed party on the other end of the transaction. An overseas parcel puts no one. You can follow where each rule stands on our regulatory tracker, and brush up on the terms in the glossary.
We will state our interest plainly, as we always do: Peppies is an independent, for-profit venture that would benefit only from a future legal, tested market, so we advocate for one. That is a disclosed position, not a neutral fact, and the rest of it lives on our about page. None of these peptides has been evaluated or approved by the FDA, nothing here is medical advice, and we make no claim that any peptide is safe or effective.
Get notified when the FDA opens the comment window that carries legal weight.
By Peppies.